Similar articles

• Predictive and protective factors associated with upper gastrointestinal bleeding after percutaneous coronary intervention: a case-control study.

  Chin MW, Yong G, Bulsara MK, Rankin J, Forbes GM. Chin MW, et al. Am J Gastroenterol. 2007 Nov;102(11):2411-6. doi: 10.1111/j.1572-0241.2007.01460.x. Epub 2007 Sep 10. Am J Gastroenterol. 2007. PMID: 17850413
• Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.

  Mehta SR, Granger CB, Eikelboom JW, Bassand JP, Wallentin L, Faxon DP, Peters RJ, Budaj A, Afzal R, Chrolavicius S, Fox KA, Yusuf S. Mehta SR, et al. J Am Coll Cardiol. 2007 Oct 30;50(18):1742-51. doi: 10.1016/j.jacc.2007.07.042. Epub 2007 Oct 15. J Am Coll Cardiol. 2007. PMID: 17964037 Clinical Trial.
• Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.

  Pride YB, Wiviott SD, Buros JL, Zorkun C, Tariq MU, Antman EM, Braunwald E, Gibson CM; TIMI Study Group. Pride YB, et al. Am Heart J. 2009 Sep;158(3):e21-6. doi: 10.1016/j.ahj.2009.06.021. Am Heart J. 2009. PMID: 19699846 Clinical Trial.
• Implications of bleeding and blood transfusion in percutaneous coronary intervention.

  Rao SV. Rao SV. Rev Cardiovasc Med. 2007;8 Suppl 3:S18-26. Rev Cardiovasc Med. 2007. PMID: 17917617 Review.
• Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.

  Motovska Z, Kala P. Motovska Z, et al. Clin Ther. 2008;30 Pt 2:2191-202. doi: 10.1016/j.clinthera.2008.12.001. Clin Ther. 2008. PMID: 19281914 Review.